Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Tamoxifen is crucial for estrogen receptor-positive breast cancer adjuvant therapy, reducing recurrence and mortality.
• Standard 20 mg daily tamoxifen doses cause significant adverse effects, leading to high discontinuation rates.
• Evidence from large trials on low-dose tamoxifen's tolerability and efficacy in adjuvant settings is limited.

Purpose of the Study:

• To review existing evidence on the tolerability and clinical efficacy of reduced tamoxifen doses.
• To analyze the impact of low-dose tamoxifen on adverse effects and quality of life.
• To evaluate the efficacy of low-dose tamoxifen in breast cancer prevention.

Main Methods:

• Extensive literature search for studies on reduced tamoxifen doses.
• Analysis of adverse event incidence and quality of life data.
• Evaluation of clinical efficacy using various endpoints in the preventive setting.

Main Results:

• Low-dose tamoxifen may reduce treatment-related toxicity and improve patient adherence.
• Data on the efficacy of reduced doses in the adjuvant setting requires further investigation.
• The review provides practical approaches for dose reduction and suggests future research directions.

Conclusions:

• Lowering tamoxifen dosage is a potential strategy to improve tolerability in breast cancer patients.
• Further research is needed to establish optimal low-dose tamoxifen regimens for individual patient needs.
• Personalized dosing strategies can enhance treatment adherence and outcomes in adjuvant tamoxifen therapy.